Fosun Pharma: The application for the listing of a new indication for a drug by a holding subsidiary has been accepted.

Fosun Pharmaceuticals announced that its holding subsidiary, Fosun Pharma Industry, has had its application for the listing of the drug Fumainin, developed independently, for the treatment of new indications accepted by the National Medical Products Administration and included in the priority review program. As of February 5, 2026, the drug has been launched in China and approved for two indications, with another application accepted for listing and two indications in the clinical trial stage. As of December 2025, the Group has accumulated approximately 663 million yuan in research and development investment for this drug. In 2024, the global sales of MEK1/2 selective inhibitors were approximately 2.068 billion US dollars. New indications need to be registered and approved for commercialization before they can be launched, and this acceptance does not affect the current performance stage.